News
Bristol Myers on Friday said the Phase 3 study of Reblozyl with concomitant janus-kinase-inhibitor therapy didn't meet its primary endpoint of red-blood-cell transfusion independence in adults with ...
Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did ...
24/7 Wall St. on MSN10m
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy NowPresident Trump recently signed the "Big, Beautiful" bill, which introduces a temporary "senior bonus" deduction of up to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback